Search clinical trials for: Hiltonol (Poly-ICLC)

Total 1380 results

AstraZeneca
Parexel

Withdrawn

A Study to Evaluate the Effectiveness and Tolerability of a Second Maintenance Treatment in Participants With Ovarian Cancer, Who Have Previously Received Polyadenosine 5'Diphosphoribose [Poly (ADP Ribose)] Polymerase Inhibitor (PARPi) Treatment. (DUETTE)

Ovarian Cancer

United States, Italy, Canada, Spain
Nordic Society of Gynaecological Oncology - Clinical...
Institute of Cancer Research, United Kingdom; Belgian Gynaecological Oncology... and other collaborators

Withdrawn

Rucaparib Maintenance Therapy in Advanced Cervical Cancer (MaRuC)

Cervical Cancer

Denmark
AbbVie

Completed

A Phase 1 Study of Single Agent Veliparib in Japanese Subjects With Advanced Solid Tumors

Advanced Solid Tumors

Japan
AstraZeneca

Completed

D081AC00001 Food Interaction With Olaparib Capsule in Patients With Solid Tumours

Solid Tumours

Belgium, United Kingdom, Netherlands
The University of Texas Health Science Center at...

Withdrawn

Combination of Carboplatin, Eribulin Mesylate, and E7449 in BRCA-Related Cancers

Cancer of the Breast
Jin Li

Not yet recruiting

Fluzoparib Combined With Apatinib in Relapsed Ovarian Carcinoma Maintenance Treatment

Relapsed Ovarian Cancer
Massachusetts General Hospital
GlaxoSmithKline

Recruiting

Niraparib In Recurrent IDH 1/2 Gliomas

Recurrent Glioma | Low-grade Glioma | Glioma, Malignant | IDH2 Gene Mutation | IDH1 Mutation

United States
Hoffmann-La Roche

Recruiting

A Phase 1 Study of RO7623066 Alone and in Combination in Patients With Advanced Solid Tumors

Advanced Solid Tumors

United States
University of Turin, Italy

Recruiting

UNITO-001- Study in HRR/PDL1 Positive MPM/NSCLC (UNITO-001)

Lung Cancer | Mesothelioma

Italy
Institute of Cancer Research, United Kingdom
AstraZeneca

Recruiting

PHOENIX DDR/Anti-PD-L1 Trial: A Pre-surgical Window of Opportunity and Post-surgical Adjuvant Biomarker Study of DNA Damage Response Inhibition and/or Anti-PD-L1 Immunotherapy in Patients With Neoadjuvant Chemotherapy Resistant Residual Triple Negative Breast Cancer (PHOENIX)

Breast Neoplasm

United Kingdom
Artios Pharma Ltd

Active, not recruiting

A Study of ART4215 for the Treatment of Advanced or Metastatic Solid Tumors

Breast Cancer | Metastatic Cancer | Advanced Cancer

United States, United Kingdom
European Organisation for Research and Treatment...
AstraZeneca

Withdrawn

Chemo-free BRCA-targeted Neoadjuvant Strategy

BRCA1 Mutation | BRCA2 Mutation | TNBC - Triple-Negative Breast Cancer
AstraZeneca

Completed

A Study to Assess the Safety and Pharmacokinetics of an Inhibitor of Poly ADP-Ribose Polymerase-1 (PARP)

Ovarian Neoplasms | BRCA1 Protein | BRCA2 Protein

Netherlands, Belgium, United Kingdom, Poland
zr Pharma & GmbH

Completed

A Study of Rucaparib in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation

Pancreatic Cancer | Pancreatic Ductal Adenocarcinoma

United States, Israel
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Talazoparib in Determining Genetic Effects on Disease Response in Patients With Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (POSITION)

Fallopian Tube Serous Adenocarcinoma | Primary Peritoneal Serous Adenocarcinoma | Stage III Fallopian Tube Cancer AJCC v7 | Stage III Ovarian Cancer AJCC v6 and v7 | Stage III Primary Peritoneal Cancer AJCC v7 | Stage IIIA Fallopian Tube Cancer AJCC v7 | Stage IIIA Ovarian Cancer AJCC v6 and v7 | Stage IIIA Primary Peritoneal Cancer AJCC v7 and other conditions

United States
Pfizer
Medivation, Inc.

Completed

A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study) (EMBRACA)

Breast Neoplasms | BRCA 1 Gene Mutation | BRCA 2 Gene Mutation

Korea, Republic of, United States, Australia, Spain, Belgium, France, Ireland, Taiwan, Poland, Germany, Israel, Brazil, United Kingdom, Italy, Russian Federation, Ukraine
Latin American Cooperative Oncology Group

Terminated

Neoadjuvant Durvalumab Alone Versus Durvalumab With Olaparib in Patients Ineligible for Cisplatin With Muscle-Invasive Urothelial Carcinoma of the Bladder Followed by Radical Cystectomy

Bladder Cancer | Urothelial Carcinoma

Brazil
Hoffmann-La Roche

Completed

A Combination Study of Rucaparib and Atezolizumab in Participants With Advanced Gynecologic Cancers and Triple-Negative Breast Cancer

Gynecologic Neoplasms

Spain, France, Australia, United Kingdom
AstraZeneca
KuDOS Pharmaceuticals Limited

Completed

Study to Assess the Efficacy and Safety of a PARP Inhibitor for the Treatment of BRCA-positive Advanced Ovarian Cancer (ICEBERG 2)

Ovarian Neoplasm

United States, Spain, Australia, Germany, Sweden
Royal Marsden NHS Foundation Trust
Institute of Cancer Research, United Kingdom

Unknown

Adaptive Planning in Bladder Cancer (APPLY)

Bladder Cancer

United Kingdom
Tianjin Medical University Cancer Institute and...

Recruiting

PD1 and PARP for Maintenance Therapy in NSLLC

Lung Cancer

China
National Cancer Institute, Naples

Recruiting

MITO 35B: Olaparib Beyond Progression Compared to Platinum Chemotherapy After Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer Patients. (MITO 35B)

Ovarian Cancer

Italy
Grupo Espanol Multidisciplinario del Cancer Digestivo
Merk Sharp & Dohme España S.A.

Recruiting

Pembrolizumab and Olaparib in Homologous-recombination Deficient (HRD) Advanced Colorectal Cancer (CRC). (PEMBROLA)

Metastatic Colorectal Cancer

Spain
M.D. Anderson Cancer Center

Recruiting

Cabozantinib and Pamiparib for the Treatment of Advanced of Refractory Solid Tumors

Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm

United States
University Health Network, Toronto
Pfizer

Recruiting

Talazoparib and Thoracic RT for ES-SCLC

Lung Cancer | Small-Cell Lung Cancer

Canada
University Health Network, Toronto

Recruiting

Study of Olaparib and Durvalumab in IDH-Mutated Solid Tumors (SOLID)

Glioma | Solid Tumor | Cholangiocarcinoma | IDH Mutation

Canada
Gustave Roussy, Cancer Campus, Grand Paris

Suspended

Basket Trial Exploring the Efficacy and Safety of the Combination of Niraparib and Dostarlimab (NIRADO)

Clear Cell Renal Cell Carcinoma | Head and Neck Cancer | Gastric Adenocarcinoma | Pancreatic Ductal Adenocarcinoma | Biliary Tract Cancer | Urothelial Bladder Cancer | Gastro-oesophageal Adenocarcinoma | Platinum-sensitive Urothelial Bladder Cancer

France
University of Parma
University of Birmingham; Azienda Ospedaliero-Universitaria di Parma; Centro...

Completed

Aggregate Metabolic Phenotypes for (Poly)Phenols: Development of an Oral (Poly)Phenol Challenge Test (OPCT) (OPCT)

Cardiometabolic Health | Individual Variability in (Poly)Phenol Metabolism

Italy
Memorial Sloan Kettering Cancer Center

Completed

Talazoparib and Avelumab in Participants With Metastatic Renal Cell Carcinoma

Metastatic Renal Cell Carcinoma | Fumarate Hydratase Deficient Renal Cell Carcinoma | Succinate Dehydrogenase Deficient Renal Cell Carcinoma

United States
University of Michigan Rogel Cancer Center
AstraZeneca; Janssen Scientific Affairs, LLC

Active, not recruiting

Trabectedin in Combination With Olaparib in Advanced Unresectable or Metastatic Sarcoma

Sarcoma | Sarcoma Metastatic

United States
National Cancer Center Hospital East
Merck Sharp & Dohme LLC

Completed

Olaparib Monotherapy and Olaparib + Pembrolizumab Combination Therapy for Ovarian Cancer (OLAPem)

Ovarian Cancer

Japan
zr Pharma & GmbH
Foundation Medicine; Myriad Genetics, Inc.

Completed

Phase 3 Study of Rucaparib as Switch Maintenance After Platinum in Relapsed High Grade Serous or Endometrioid Ovarian Cancer (ARIEL3) (ARIEL3)

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cancer

United States, Spain, Belgium, Australia, Israel, Germany, France, United Kingdom, Italy, Canada, New Zealand
Tesaro, Inc.
Gynecologic Oncology Group

Terminated

Study to Evaluate the Efficacy and Safety of the Combination of Niraparib and Dostarlimab (TSR-042) in Participants With Platinum Resistant Ovarian Cancer (MOONSTONE)

Ovarian Neoplasms

United States
Saitama Medical University International Medical...
National Cancer Center, Japan; Tokyo University; Cancer Institute Hospital, Japan and other collaborators

Active, not recruiting

Pembrolizumab Plus Olaparib in Patients With Recurrent Cervical Cancer

Cervical Cancer

Japan
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Talazoparib Before Standard Therapy in Treating Patients With Invasive, BRCA-Mutated Breast Cancer

Invasive Breast Carcinoma | HER2/Neu Negative | Breast Adenocarcinoma | Deleterious BRCA1 Gene Mutation | Deleterious BRCA2 Gene Mutation

United States
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Withdrawn

Study of M4344 in Combination With Niraparib

Breast Cancer | Advanced Solid Tumor
Seoul National University Hospital
AstraZeneca

Active, not recruiting

Window of Opportunity Trial of Neoadjuvant Olaparib and Durvalumab for Triple Negative or Low ER+ Breast Cancer

Breast Neoplasms

Korea, Republic of
AbbVie (prior sponsor, Abbott)

Completed

A Phase I Study of ABT-888 in Combination With Conventional Whole Brain Radiation Therapy (WBRT) in Cancer Patients With Brain Metastases

Brain Diseases | Central Nervous System Diseases | Neoplasm Metastasis | Brain Neoplasms | Nervous System Neoplasms

United States, Canada, Puerto Rico
AbbVie

Completed

A Study to Evaluate the Effects of Veliparib on Heart Rhythms in Patients With Solid Tumors

Breast Cancer | Gastric Cancer | Ovarian Cancer | Lung Cancer | Colon Cancer | Solid Tumors

United States, Netherlands, Spain
Institut du Cancer de Montpellier - Val d'Aurelle

Terminated

A Trial Evaluating Concurrent Whole Brain Radiotherapy and Iniparib in Multiple Non Operable Brain Metastases (RAPIBE)

Brain Metastases

France
Institut Curie
AstraZeneca

Completed

Olaparib & Radiation Therapy for Patients Triple Negative Breast Cancer (TNBC) (RadioPARP)

Radiotherapy Side Effect | Breast Neoplasm Malignant Female | Breast Neoplasms, Triple-Negative

France
Restor3D

Terminated

A Prospective Study to Evaluate the iTotal Knee and iPoly XE Tibial Inserts

Knee Osteoarthritis

Germany
University of Virginia
DexCom, Inc.; Tandem Diabetes Care, Inc.; Virginia Research Investment Fund

Completed

The VRIF Trial: Hypoglycemia Reduction With Automated-Insulin Delivery System

Cognitive Change | Type 1 Diabetes Mellitus

United States
University Medical Centre Ljubljana

Recruiting

Cytomegalovirus Prophylaxis With Letermovir in Heart Transplant Recipients (CYPHER-TXPilot)

CMV Viremia

Slovenia
Gustave Roussy, Cancer Campus, Grand Paris

Recruiting

Safety and Efficacy of AsiDNATM, a DNA Repair Inhibitor, Administered Intravenously in Addition to PARP Inhibitors in Patients With Relapsed Platinum Sensitive Ovarian Cancer Already Treated With PARP Inhibitors Since at Least 6 Months (REVOCAN)

Ovarian Cancer

France
Shandong University
Sun Yat-sen University; Zai Lab (Shanghai) Co., Ltd.; Tongji Hospital; Women's...

Recruiting

Niraparib Monotherapy as Maintain and Recurrent Treatment of Endometrial Serous Carcinoma

Endometrial Carcinoma | Serous Carcinoma

China
IRCCS Eugenio Medea
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico; University of Milan

Recruiting

Poly-unsaturated Fatty Acids and Developmental Dyslexia

Dyslexia, Developmental

Italy
National University Hospital, Singapore

Recruiting

Phase I Study of AZD5363 + Olaparib + Durvalumab in Patients With Advanced or Metastatic Solid Tumor Malignancies (MEDIPAC)

Solid Tumor, Adult

Singapore
University of Alabama at Birmingham
Tesaro, Inc.; Susan G. Komen Breast Cancer Foundation; Translational Breast Cancer... and other collaborators

Recruiting

Niraparib in Combination With Trastuzumab in Metastatic HER2+ Breast Cancer

Metastatic Breast Cancer | HER2 Positive Breast Carcinoma

United States
AstraZeneca
Merck Sharp & Dohme LLC; European Network of Gynaecological Oncological Trial... and other collaborators

Active, not recruiting

Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy

Relapsed Ovarian Cancer | Following Complete or Partial Response to Platinum Based Chemotherapy | Platinum Sensitive | BRCA Mutated

Korea, Republic of, France, China, Italy, United States, Israel, United Kingdom, Canada, Japan, Germany, Brazil, Netherlands, Belgium, Poland, Australia, Russian Federation, Spain

Search clinical trials for: Hiltonol (Poly-ICLC)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ecuador

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations